Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000902664-25-002179
Filing Date
2025-05-08
Accepted
2025-05-08 16:39:53
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10034
2 EXHIBIT D: MAY 8 PRESS RELEASE p25-1124exhibitd.htm EX-99 25557
3 EXHIBIT E LETTER p25-1124exhibite.htm EX-99 15637
4 GRAPHIC image_001.jpg GRAPHIC 34634
  Complete submission text file 0000902664-25-002179.txt   100746
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91484 | Film No.: 25926958
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738
Business Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738 512-254-3790
ADAR1 Capital Management, LLC (Filed by) CIK: 0001940272 (see all company filings)

EIN.: 000000000 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13D/A